small molecule

FOUNDAYO

ORFORGLIPRON CALCIUM

Loss of exclusivitySeptember 2037latest FDA-listed patent expiry

CompanyELI LILLY AND CO

Drug detail

Brand name	FOUNDAYO
Active ingredient	ORFORGLIPRON CALCIUM
Strength	EQ 9MG BASE
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
RE50455	September 2037	substance, product

Regulatory exclusivity

Code	Expires
NCE	April 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ELI LILLY AND CO